Parameter
| Biomarker | Ikaros-pSer442/445 | Full name | Ikaros-pSer442/445 | Molecular Type | Protein (phosphorylation) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Predicting treatment response | ||
| Disease | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | / | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | Tissues, cell lines (phosphoproteomics, RNA-seq) | ||
| Pathobiological Mechanisms | TG-1701 attenuates its signal, correlating with early clinical response | ||||
| Clinical Availability Status | Research Validation Phase: Validation of 6 CLL patients, requiring B-NHL subtype validation and development of detection methods. | ||||
| Notes and Dynamics | Validation of subtypes applicability and development of immunohistochemical detection for phosphorylated proteins. | ||||